It has underperformed by 16.70% the S&P500.
Today we are spotlighting shares of Abeona Therapeutics Inc. Therefore 100% are positive. HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of Abeona Therapeutics in a research report on Thursday, August 24th. $22.43's average target is 19.63% above currents $18.75 stock price. BidaskClub downgraded Abeona Therapeutics from a buy rating to a hold rating in a research report on Wednesday, August 2nd.
10/6/2017-Cantor Fitzgerald Reiterated Rating of Buy. The firm has "Buy" rating given on Wednesday, December 16 by Maxim Group. The stock of Abeona Therapeutics Inc (NASDAQ:ABEO) earned "Outperform" rating by RBC Capital Markets on Friday, September 15. The firm earned "Buy" rating on Tuesday, August 11 by TheStreet. Jefferies maintained Abeona Therapeutics Inc (NASDAQ:ABEO) rating on Friday, September 22. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. Jefferies has "Buy" rating and $21.0 target. The stock has a consensus rating of "Buy" and a consensus target price of $21.44.
While having a peek at profitability ratios Abeona Therapeutics (NASDAQ:ABEO) has trailing twelve month gross margin at 0%, its trailing twelve month operating margin stands at 0% whereas its trailing twelve month net profit margin spots at 0%. The company's forward price to earnings ratio for next fiscal year is 0.
Analysts expect Abeona Therapeutics Inc (NASDAQ:ABEO) to report $-0.16 EPS on November, 13.They anticipate $0.08 EPS change or 100.00 % from last quarter's $-0.08 EPS.
On 9/20/2016 Todd Wider, Director, bought 5,000 with an average share price of $5.48 per share and the total transaction amounting to $27,400.00. Abeona Therapeutics Inc (NASDAQ:ABEO) has risen 151.02% since October 11, 2016 and is uptrending.
Abeona Therapeutics Inc. focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company has market cap of $733.91 million.
As of the last earnings report the EPS was $-0.61 and is expected to be $-0.68 for the current year with 40,287,000 shares presently outstanding. It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy for rare blood diseases.
10/10/2017-Citigroup Inc. initiated coverage with a Buy rating. The Earnings Yield Five Year average for Co-Prosperity Holdings Limited (SEHK:707) is -0.014207. Abeona Therapeutics earned a coverage optimism score of 0.24 on Accern's scale.
The Return on Invested Capital (aka ROIC) for Gefran S.p.A. (BIT:GE) is 0.148861. Its up 0.01, from 0.99 in 2017Q1. RSI is a technical indicator of price momentum, comparing the size of recent gains to the size of recent losses and establishes oversold and overbought positions. 138 funds opened positions while 500 raised stakes. Moller Svcs has 37,915 shares. Burt Wealth Advisors accumulated 3,106 shares. The current ratio, also known as the working capital ratio, is a liquidity ratio that displays the proportion of current assets of a business relative to the current liabilities. Next quarter's EPS is estimated at $-0.17 with next year's EPS projected to be $-0.77. Out of 3 Wall Street analysts rating Grainger, 1 give it "Buy", 1 "Sell" rating, while 1 recommend "Hold". Coho Partners Ltd. owns 693,866 shares or 3.13% of their USA portfolio.
The top 5 institutional holders, in ascending order, are as follows: KNOLL CAPITAL MANAGEMENT, LP with 2.36 million shares, ADAGE CAPITAL PARTNERS GP, L.L.C. with 1.95 million shares, BAKER BROS.
Since May 15, 2017, it had 3 insider buys, and 0 insider sales for $3.37 million activity.